TBIIF yields 1036.27% · JNJ yields 2.13%● Live data
📍 TBIIF pulled ahead of the other in Year 1
Combined, TBIIF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TBIIF + JNJ for your $10,000?
Tobii AB (publ) develops and sells eye-tracking technology and solutions in Sweden, rest of Europe, the United States, Canada, Asia/Oceania, and internationally. It operates in two segments, Products & Solutions, and Integrations. The Products & solutions segments provides a suite of eye tracking hardware, which includes the Tobii Pro Glasses 3; research-grade and screen-based eye trackers, such as Pro Spectrum and Pro Fusion; and the Tobii Eye Tracker 5, a gaming eye tracker. This segment also includes software Tobii Pro Lab, Sticky, and the consultancy service Tobii Pro Insight. The Integration segment offers algorithms, software, hardware components, system reference designs, and IP-licenses to provide tailored solutions to address industry-specific problems. It serves the scientific studies and research, healthcare, assistive devices, education and training, gaming, extended reality, automotive, and other sectors. The company offers its products through resellers, agents, and distributors. Tobii AB (publ) was founded in 2001 and is headquartered in Danderyd, Sweden.
Full TBIIF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.